MEK signaling found to drive T-cell exhaustion in cancer immunotherapy

· Science · United States

Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer Center identified a signaling molecule called MEK that can push T cells to burn through their energy while producing cancer-fighting compounds. According to ScienceDaily, targeting this pathway could help sustain T cells in the fight against tumors. T-cell exhaustion is a major obstacle limiting the effectiveness of immunotherapies such as CAR-T and checkpoint inhibitors. The finding suggests that blocking MEK might extend the useful life of engineered T cells, potentially improving outcomes for patients whose tumors stop responding.

Why it matters：T-cell exhaustion limits the reach of the fast-growing immunotherapy field, so a druggable target like MEK could influence the next wave of cancer treatment development.

Key points

  • MEK pushes T cells to burn through their energy.
  • The finding comes from Memorial Sloan Kettering Cancer Center.
  • Targeting MEK could sustain T cells in fighting tumors.

Sources (original reporting)

More stories from this day